Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non–Small Cell Lung Cancer: Updated Analysis of the RESET Study

PURPOSE: This study aimed to report the final analysis of time-on-treatment (TOT) and overall survival (OS) in patients with advanced-stage epidermal growth factor receptor (EGFR)+ non–small cell lung cancer (NSCLC) who received sequential afatinib and osimertinib and to compare the outcomes with ot...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Taeyun, Jang, Tae Won, Choi, Chang Min, Kim, Mi-Hyun, Lee, Sung Yong, Chang, Yoon Soo, Lee, Kye Young, Kim, Seung Joon, Yang, Sei Hoon, Ryu, Jeong Seon, Lee, Jeong Eun, Lee, Shin Yup, Park, Chan Kwon, Lee, Sang Hoon, Jang, Seung Hun, Yoon, Seong Hoon, Oh, Hyung-Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582551/
https://www.ncbi.nlm.nih.gov/pubmed/37218139
http://dx.doi.org/10.4143/crt.2023.493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582551/
https://www.ncbi.nlm.nih.gov/pubmed/37218139
http://dx.doi.org/10.4143/crt.2023.493

Ejemplares similares